Amino acid-derived 1,2-benzisothiazolinone derivatives as novel small-molecule antifungal inhibitors: Identification of potential genetic targets

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 9, 2012, Pages 4630-4639

  Alex, Deepu ^a   Gay Andrieu, Francoise ^a,c   May, Jared ^a   Thampi, Linta ^a   Dou, Dengfeng ^b   Mooney, Aileen ^a   Groutas, William ^b   Calderone, Richard ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b WICHITA STATE UNIVERSITY   (United States)

^c UNIVERSITÉ DE NANTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 BENZISOTHIAZOLINONE DERIVATIVE; AMINO ACID DERIVATIVE; AMPHOTERICIN B; ANTIFUNGAL AGENT; BENZOTHIAZOLINE DERIVATIVE; FLUCONAZOLE; GLYCEROL; MICAFUNGIN; POLYENE ANTIBIOTIC AGENT; PYRROLE DERIVATIVE; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANAEROBIC GROWTH; ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS FUMIGATUS; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CELL GROWTH; CLAVISPORA LUSITANIAE; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; CULTURE MEDIUM; DRUG STRUCTURE; DRUG TARGETING; ENERGY YIELD; EPIDERMOPHYTON FLOCCOSUM; FUNGAL CELL; FUNGAL STRAIN; FUNGICIDAL ACTIVITY; FUNGUS GROWTH; FUNGUS IDENTIFICATION; FUNGUS MUTANT; GENE CLUSTER; GENE DELETION; GENE TARGETING; GLYCOLYSIS; HOMOZYGOSITY; IC 50; MICROSPORUM CANIS; MINIMUM INHIBITORY CONCENTRATION; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; PHENOTYPE; PICHIA GUILLIERMONDII; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; TRICHOPHYTON MENTAGROPHYTES; TRICHOPHYTON RUBRUM;

AMINO ACIDS; ANTIFUNGAL AGENTS; ARTHRODERMATACEAE; ASPERGILLUS FUMIGATUS; CANDIDA ALBICANS; CRYPTOCOCCUS NEOFORMANS; DRUG RESISTANCE, MULTIPLE, FUNGAL; FUNGAL PROTEINS; GLYCEROL; GLYCOLYSIS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICROBIAL SENSITIVITY TESTS; MITOCHONDRIA; MUTATION; SACCHAROMYCES CEREVISIAE; THIAZOLES; TRANSCRIPTION FACTORS;

EID: 84865434996     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00477-12     Document Type: Article

References (63)

1. Alex D, Calderone R, Li D. 2012. Back to the future: Candida mitochondria and energetics, p 331-343. In Calderone R, Clancy CJ (ed), Candida and candidiasis. ASM Press, Washington, DC.
2. Altmann K, Westermann B. 2005. Role of essential genes in mitochondrial morphogenesis. Mol. Biol. Cell 16:5410-5417.
3. Bambach A, et al. 2009. Goa1p of Candida albicans localizes to the mitochondria during stress and is required for mitochondrial function and virulence. Eukaryot. Cell 8:1706-1720.
4. Barchiesi F, Falconi Di Francesco L, Scalise G. 1997. In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles. Antimicrob. Agents Chemother. 41:1812-1814. (Pubitemid 27339894)
5. Batova M, et al. 2010. Chemogenomic and transcriptome analysis identifies mode of action of the chemosensitizing agent CTBT (7- chlorotetrazolo[5,1-c] benzo[1,2,4]triazine). BMC Genomics 11:153.
6. Bidlingmaier S, Weiss EL, Seidel C, Drubin DG, Snyder M. 2001. The Cbk1p pathway is important for polarized cell growth and cell separation in Saccharomyces cerevisiae. Mol. Cell. Biol. 21:2449-2462. (Pubitemid 32222097)
7. Blignaut E. 2007. Oral candidiasis and oral yeast carriage among institutionalized South African paediatric HIV/AIDS patients. Mycopathologia 163:67-73.
8. Boucher HW, et al. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48:1-12.
9. Bredel M, Jacoby E. 2004. Chemogenomics: an emerging strategy for rapid target and drug discovery. Nat. Rev. Genet. 5:262-275. (Pubitemid 38435622)
10. Canton E, Peman JA, Valentin A, Espinel-Ingroff A, Gobernado M. 2009. In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. Antimicrob. Agents Chemother. 53: 3108-3111.
11. Chakrabarti A, Chatterjee SS, Shivaprakash MR. 2008. Overview of opportunistic fungal infections in India. Nihon Ishinkin Gakkai Zasshi 49:165-172.
12. Chakraborty N, et al. 2008. Current trends of opportunistic infections among HIV-seropositive patients from Eastern India. Jpn. J. Infect. Dis. 61:49-53. (Pubitemid 351338530)
13. Chamilos G, Lewis RE, Kontoyiannis DP. 2006. Inhibition of Candida parapsilosis mitochondrial respiratory pathways enhances susceptibility to caspofungin. Antimicrob. Agents Chemother. 50:744-747. (Pubitemid 43190991)
14. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard - third edition. Clinical and Laboratory Standards Institute, Wayne, PA.
15. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard - second edition. Clinical and Laboratory Standards Institute, Wayne, PA.
16. Coste A, et al. 2007. Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates. Eukaryot. Cell 6:1889-1904. (Pubitemid 47585577)
17. Coste A, et al. 2006. A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans. Genetics 172:2139-2156.
18. Dou D, et al. 2011. Antifungal activity of a series of 1,2-benzisothiazol-3(2H)-one derivatives. Bioorg. Med. Chem. 19:5782-5787.
19. Dunkel N, Blass J, Rogers PD, Morschhauser J. 2008. Mutations in the multi-drug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole-resistant Candida albicans strains. Mol. Microbiol. 69:827-840. (Pubitemid 352033303)
20. Fidel P, Jr. 2006. Candida-host interactions in HIV disease: relationships in oropharyngeal candidiasis. Adv. Dent. Res. 19:80-84.
21. Gagne JJ, Goldfarb NI. 2007. Candidemia in the in-patient setting: treatment options and economics. Expert Opin. Pharmacother. 8:1643-1650. (Pubitemid 47296549)
22. Garcia-Effron G, Katiyar SK, Park S, Edlind TD, Perlin DS. 2008. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob. Agents Chemother. 52:2305-2312. (Pubitemid 351915657)
23. Hachem R, Hanna H, Kontoyiannis D, Jiang Y, Raad I. 2008. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 112:2493-2499.
24. Hawser S, Islam K. 1999. Comparisons of the effects of fungicidal and fungistatic antifungal agents on the morphogenetic transformation of Candida albicans. J. Antimicrob. Chemother. 43:411-413. (Pubitemid 29121883)
25. Hillenmeyer ME, et al. 2008. The chemical genomic portrait of yeast: uncovering a phenotype for all genes. Science 320:362-365. (Pubitemid 351555656)
26. Hodgetts S, et al. 2008. Efungumab and caspofungin: pre-clinical data supporting synergy. J. Antimicrob. Chemother. 61:1132-1139. (Pubitemid 351524461)
27. Hoon S, et al. 2008. An integrated platform of genomic assays reveals small molecule bioactivities. Nat. Chem. Biol. 4:498-506.
28. Indran I, Tufo G, Pervaiz S, Brennen C. 2011. Recent advances in apoptosis, mitochondria and drug resistance in cancer cells. Biochim. Biophys. Acta 1807:735-745.
29. Jabra-Rizk MA, et al. 2001. Prevalence of yeast among children in Nigeria and the United States. Oral Microbiol. Immunol. 16:383-385. (Pubitemid 33066035)
30. Kamran M, et al. 2004. Inactivation of the transcription factor ACE2 in the fungal pathogen Candida glabrata results in hypervirulence. Eukaryot. Cell 3:546-552. (Pubitemid 38497992)
31. Kelly M, et al. 2004. The Candida albicans gene ACE2 affects morphogenesis, adherence, and virulence. Mol. Microbiol. 53:969-983. (Pubitemid 39036973)
32. Lass-Florl C. 2009. The changing face of epidemiology of invasive fungal disease in Europe. Mycoses 52:197-205.
33. Li D, et al. 2011. Enzymatic dysfunction of mitochondrial complex I of the Candida albicans goa1 mutant is associated with increased reactive oxidants and cell death. Eukaryot. Cell 10:672-682.
34. Lopez-Ribot JL, et al. 1998. Distinct patterns of gene expression associated with development of fluconazole resistance in serial Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob. Agents Chemother. 42:2932-2937. (Pubitemid 28501228)
35. Marr KA, Lyons CN, Rustad TR, Bowden R, White T. 1998. Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR. Antimicrob. Agents Chemother. 42:2584- 2589.
36. Micol R, et al. 2010. Cost-effectiveness of primary prophylaxis of AIDS associated cryptococcosis in Cambodia. PLoS One 5:e13856. doi:10.1371/ journal.pone.0013856.
37. Miller LG, Hajjeh RA, Edwards JE, Jr. 2001. Estimating the cost of nosocomial candidemia in the United States. Clin. Infect. Dis. 32:1110. (Pubitemid 32299650)
38. Morio F, Loge C, Besse B, Hennequin C, Le Pape P. 2010. Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature. Diagn. Microbiol. Infect. Dis. 66:373-384.
39. Morschhauser J, et al. 2007. The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathog. 3:e164. doi:10.1371/journal.ppat. 0030164.
40. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65:55-63. (Pubitemid 14203433)
41. Mulhern SM, Logue ME, Butler G. 2006. Candida albicans transcription factor Ace2 regulates metabolism and is required for filamentation in hypoxic conditions. Eukaryot. Cell 5:2001-2013. (Pubitemid 44956812)
42. Mullan PC, et al. 2011. Etiology of meningitis among patients admitted to a tertiary referral hospital in Botswana. Pediatr. Infect. Dis. J. 30:620-622.
43. Okome-Nkoumou M, Mbounja-Loclo ME, Kombila M. 2000. Spectrum of opportunistic infections in subjects infected with HIV at Libreville, Gabon. Sante 10:329-337. (In French.) (Pubitemid 32107144)
44. Olaechea PM, et al. 2004. Economic impact of Candida colonization and Candida infection in the critically ill patient. Eur. J. Clin. Microbiol. Infect. Dis. 23:323-330. (Pubitemid 38669943)
45. Ostrosky-Zeichner L, Casadevall A, Galgiani JN, Odds FC, Rex JH. 2010. An insight into the antifungal pipeline: selected new molecules and beyond. Nat. Rev. Drug Discov. 9:719-727.
46. Perlin DS. 2007. Resistance to echinocandin-class antifungal drugs. Drug Resist. Update 10:121-130. (Pubitemid 47031054)
47. Pfaller MA, Castanheira M, Messer SA, Moet GJ, Jones RN. 2010. Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008-2009). Diagn. Microbiol. Infect. Dis. 68:278-283.
48. Pfaller MA, Diekema DJ. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20:133-163. (Pubitemid 46167771)
49. Pfaller MA, Diekema DJ, International Fungal Surveillance Participant Group. 2004. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin. Microbiol. Infect. 10(S1):11-23. (Pubitemid 38386593)
50. Repetto G, del Peso A, Zurita JL. 2008. Neutral red uptake assay for the estimation of cell viability/cytotoxicity. Nat. Protoc. 3:1125-1131.
51. Robinson MD, Grigull J, Mohammad N, Hughes TR. 2002. FunSpec: a web-based cluster interpreter for yeast. BMC Bioinformatics 3:35.
52. Smith AM, Ammar R, Nislow C, Giaever G. 2010. A survey of yeast genomic assays for drug and target discovery. Pharmacol. Ther. 127:156-164.
53. Sobel JD. 2007. Vulvovaginal candidosis. Lancet 369:1961-1971. (Pubitemid 46874580)
54. Trofa D, Gacser A, Nosanchuk JD. 2008. Candida parapsilosis, an emerging fungal pathogen. Clin. Microbiol. Rev. 21:606-625.
55. Uppuluri P, Nett J, Heitman J, Andes D. 2008. Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. Antimicrob. Agents Chemother. 52:1127-1132. (Pubitemid 351358397)
56. Vandeputte P, et al. 2008. A nonsense mutation in the ERG6 gene leads to reduced susceptibility to polyenes in a clinical isolate of Candida glabrata. Antimicrob. Agents Chemother. 52:3701-3709.
57. Wang CH, Wang CC, Wei YH. 2010. Mitochondrial dysfunction and insulin insensitivity: implication of mitochondrial role in type 2 diabetes. Ann. N. Y. Acad. Sci. 1201:157-165.
58. Warkentien T, Crum-Cianflone NF. 2010. An update on Cryptococcus among HIV-infected patients. Int. J. STD AIDS 21:679-684.
59. White TC, Holleman S, Dy F, Mirels L, Stevens DD. 2002. Resistant mechanisms in clinical isolates of Candida albicans. Antimicrob. Agents Chemother. 46:1704-1713. (Pubitemid 34535186)
60. Wilson LS, et al. 2002. The direct cost and incidence of systemic fungal infections. Value Health 5:26-34. (Pubitemid 34160368)
61. Yan L, Yi M, Cao Y, Gao P, Cao Y. 2009. The alternate oxidase of Candida albicans causes reduced fluconazole susceptibility. J. Antimicrob. Chem. 64:764-773.
62. Zhang X, Reichart PA, Song Y. 2009. Oral manifestations of HIV/AIDS in China: a review. Oral Maxillofac. Surg. 13:63-68.
63. Zhu J, Chu CT. 2010. Mitochondrial dysfunction in Parkinson's disease. J. Alzheimers Dis. 20(Suppl 2):S325-S334.